To experimentally address the intrinsic drug resistance of mesenchymal‐shifted SCLC cells to LSD1 inhibitors, we treated a mesenchymal variant form of NCI‐H69 cells, NCI‐H69V [43] with GSK690. The gene discussed is KDM1A; the disease is small cell lung carcinoma.